The Pharmacy Guild of Australia, representing almost 5,000 community pharmacies across Australia, is acutely aware of the need to ensure the professional practice of pharmacy is provided with the most up-to-date technology available. Not just technology for its own sake, but useful tools that help modern pharmacists perform to their full potential as frontline health professionals.
That’s why the Guild entered an agreement with its United States counterpart – the National Community Pharmacists’ Association (NCPA) – to launch Mirixa Australia and adapt the MirixaPro™ clinical web-based platform for use across Australia.
Mirixa Corporation, a subsidiary of NCPA, is a leading provider of clinical health information technologies and consumer health services for pharmacy in the United States. They understand the complexities of modern pharmacy and develop the technological solutions needed to deliver medication-related patient care. Most importantly, they strive to enable pharmacists to improve safety and outcomes through total medication management.
Mirixa Australia programs address some of Australia’s major healthcare challenges, including lack of proper medicines adherence/compliance, poorly coordinated patient care, and unchecked adverse drug events. Mirixa Australia solutions improve the quality of care delivered, reduce total healthcare costs, and deliver a more personalised healthcare experience.
There is no doubt that there is a need for improved system of delivery for medicines to improve national healthcare outcomes. Medicine-related hospitalisations are a major health problem in Australia – and an avoidable one. Australian research has found that at least 80 000 medicine-related hospitalisations occur in Australia each year. Between 30% and 70% of these hospitalisations are considered avoidable. Much can and should be done to reduce this problem.
We believe that integrating the pharmacist more directly into the care delivery system ensures that the system works best. Doctors, pharmacists and patients working together deliver a positive impact on care and cost. It is the next step in achieving a system of accessible, responsive, truly personalised medicine for patients.